Asthma News

WASHINGTON — Airways plugged with mucus experience more remodeling than airways that have not been plugged with mucus among patients with asthma, according to data presented at the American Thoracic Society International Conference.

WASHINGTON — More patients with asthma and insomnia had obstructive sleep apnea, depression and worse exacerbations than patients without insomnia, according to research presented at the American Thoracic Society International Conference.

WASHINGTON — Children with asthma did not see any significant differences in lung function or symptom control up to 18 months after acute COVID-19, according to data presented at the American Thoracic Society International Conference.

WASHINGTON — Women with asthma had worse disease control and higher risks for exacerbations compared with men, according to data presented at the American Thoracic Society International Conference.

WASHINGTON — Fractional exhaled nitric oxide represents a noninvasive marker of airway inflammation with good longitudinal fidelity among patients with severe asthma, according to data presented here.

Patients often go online when they experience symptoms they do not understand. But when these symptoms involve asthma, even websites from professional and governmental organizations may fall short in providing what patients need.

WASHINGTON — Pregnant women who have both asthma and obstructive sleep apnea have increased central airways resistance, but not increased peripheral airways resistance, according to a presentation here.

WASHINGTON — Patients with asthma experienced fast and substantial reductions in fractional exhaled nitric oxide with the SAR443765 bifunctional NANOBODY molecule, which blocks thymic stromal lymphopoietin and IL-13, according to a study.

WASHINGTON — A correlation between DeMeester scores and respiratory indicators approached statistical significance in patients with bronchodilator response and pathological gastroesophageal reflux disease.

WASHINGTON — Tezepelumab reduced annualized asthma exacerbation rates compared with placebo among patients with severe, uncontrolled asthma regardless of prior omalizumab use, according to study results.